Brief: HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results And Renewal Of Normal Course Issuer Bid
09/11/2023 12:21
Nov 9 (Reuters) - Hls Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS ANNOUNCES Q3 FISCAL 2023 FINANCIAL
RESULTS AND
RENEWAL OF NORMAL COURSE ISSUER BID
* SAYS Q3 2023 REVENUE WAS $16.0 MILLION, COMPARED TO $15.7
MILLION IN Q3 2022
* QTRLY LOSS $0.21 PER SHARE
* Q3 REVENUE VIEW $16.3 MILLION -- LSEG IBES DATA
Source text for Eikon: ID:nCNWb0kGFa
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsBrief: Hls Therapeutics Increases Normal Course Issuer Bid
Brief: HLS Therapeutics Announces Q2 2026 Financial Results
Canada's HLS Therapeutics Q2 revenue rises on higher cardiovascular drugs demand
Brief: HLS Therapeutics - Secures Nilemdo Reimbursement With Private Payers Covering 80% Of Privately Insured Canadians
Canada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group